CML-CP: TKI discontinuation feasible at first as well as second attempt

Key clinical point: Tyrosine kinase inhibitor (TKI) discontinuation was feasible and safe not only at the first but also at the second attempt in patients with chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: At the first attempt of TKI discontinuation, 28 patients achieved sustained treatment-free remission (TFR, 53.4%; 95% confidence interval [CI], 39.0%-65.9%) at 1 year. Among the 10 patients who attempted the second TKI discontinuation, 4 achieved the second TFR at 1 year (TFR, 37.5%; 95% CI, 9.9%-65.9%). Other 6 patients with the second relapse achieved at least a major molecular response within 6 months after resuming TKI treatment.

Study details: Findings are from a retrospective analysis of 53 patients with Philadelphia chromosome-positive CML-CP who attempted TKI discontinuation following a durable deep molecular response on TKI therapy.

,

Disclosures: This work was supported by the Shinnihon Foundation of Advanced Medical Treatment Research, Okinaka Memorial Institute for Medical Research, and the Japan Society for the Promotion of Science. S Kimura reported ties with various pharmaceutical companies. Other authors declared no conflicts of interest.

Source: Ureshino H et al. Hematol Oncol. 2021 Jun 11. doi: 10.1002/hon.2896.